Search

Author/Creator Barve, Minal A

1. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Issue 12 (December 2020)

Authors:
Rocconi, Rodney P; Grosen, Elizabeth A; Ghamande, Sharad A; Chan, John K; Barve, Minal A; Oh, Jonathan; Tewari, Devansu; Morris, Peter C; Stevens, Erin E; Bottsford-Miller, Justin N; Tang, Min; Aaron, Phylicia; Stanbery, Laura; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Manning, Luisa; N...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 12(2020)
Page Start:
1661
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Issue 10277 (6th March 2021)

Authors:
Mato, Anthony R; Shah, Nirav N; Jurczak, Wojciech; Cheah, Chan Y; Pagel, John M; Woyach, Jennifer A; Fakhri, Bita; Eyre, Toby A; Lamanna, Nicole; Patel, Manish R; Alencar, Alvaro; Lech-Maranda, Ewa; Wierda, William G; Coombs, Catherine C; Gerson, James N; Ghia, Paolo; Le Gouill, Steven; Lewis, Da...
Journal:
Lancet
Issue:
Volume 397:Issue 10277(2021)
Page Start:
892
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search